Psychiatry and Mental Health

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Guest: Joseph F. Goldberg, MD

Guest: Manpreet Kaur Singh, MD, MS

This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Host: Ashley Baker, MSN, PMHNP

Guest: Kathleen Nadeau, PhD

Girls and women with ADHD are often underdiagnosed and undertreated compared to boys and men, which puts them at risk of serious issues like unplanned pregnancies, cigarette smoking, and even anxiety and depression. To help us better identify and manage girls and women with ADHD, psychiatric nurse practitioner Ashley Baker speaks with Dr. Kathleen Nadeau, Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.

Guest: Kathleen Nadeau, PhD

It’s important to be aware of the different ways ADHD impacts girls and women compared to boys and men, which is why Dr. Kathleen Nadeau is here to help shed light on those differences. Dr. Nadeau is the Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.

Host: Christoph U. Correll, MD

Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

Host: Leslie Citrome, MD, MPH

Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

Host: Christoph U. Correll, MD

Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

Host: Leslie Citrome, MD, MPH

Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.